Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole
An Open-Label, Relative Bioavailability Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ropinirole Implants in Patients With Parkinson's Disease Switched From Oral Immediate-Release Ropinirole While on L-Dopa
Sponsor: Titan Pharmaceuticals
Terminated
This study was terminated for reasons not related to efficacy or safety
Other terminated trials from Titan Pharmaceuticals
Other Parkinson Disease trials with similar outcome
A PHASE1/PHASE2 clinical study on Parkinson Disease, this trial is terminated or withdrawn. The trial is conducted by Titan Pharmaceuticals and has accumulated 11 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2023 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Mar 2023 — Jun 2023 [monthly]
Terminated PHASE1_PHASE2
-
Apr 2022 — Mar 2023 [monthly]
Terminated PHASE1_PHASE2
▶ Show 6 earlier versions
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE1_PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
Status: Recruiting → Terminated
-
May 2019 — Mar 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — May 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Titan Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .